

Publications

Publications: Total: 21|. Number of citations: 518 (updated 21aug2026)

Publications (level 2 journal publications in bold):

1. Kvam TM, Goksøyr IW, Stewart LH, Berthold-Losleben M, Autran I, Andreassen OA. Clinical and non-clinical use of MDMA. *Tidsskr Nor Laegeforen*. 2026;146(8).
2. Kvam TM. A Clinical Trial of MDMA-Assisted Therapy for Major Depressive Disorder and Survey of Psychedelic Use: University of Oslo; 2026.
3. **Kvam T-M, Goksøyr IW, Rog J, van de Vooren I-TJ, Stewart LH, Autran I, et al. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study – CORRIGENDUM. *The British Journal of Psychiatry*. 2026:1–.**
4. **Kvam T-M, Goksøyr IW, Rog J, Autran I, Berthold-Losleben M, Andreassen OA. MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al. *The British Journal of Psychiatry*. 2026:1–2.**
5. Tunstad PA, Kvam TM, Uthaug MV, Stewart LH, Andersen KAA, Gronnerod C. Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample. *Front Pharmacol*. 2025;16:1556299.
6. **Kvam TM, Goksøyr IW, Rog J, van de Vooren IJ, Stewart LH, Autran I, et al. MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial. *J Psychiatr Res*. 2025;193:302–8.**
7. **Kvam TM, Goksøyr IW, Rog J, van de Vooren IJ, Stewart LH, Autran I, et al. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. *The British journal of psychiatry : the journal of mental science*. 2025:1–7.**
8. **Kvam T-M, Goksøyr IW, Rog J, Jentoft van de Vooren I-T, Stewart LH, Autran I, et al. MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial. *Journal of Psychiatric Research*. 2025.**
9. Gronnerod C, Ronningen T, Haugsja IR, Andersen KAA, Lindvall Dahlgren C, Kvam TM. Recreational MDMA use in Norway: results from an internet convenience sample. *Front Psychiatry*. 2025;16:1619676.
10. Berthold-Losleben M, Autran I, Folstad RLS, Romer B, Kvam TM, van de Vooren IT, et al. Ketamine in treatment-resistant depression. *Tidsskr Nor Laegeforen*. 2025;145.
11. **Andersen KAA, Holmøy B, Kvam TM, Johnson MW. Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire. *J Psychiatr Res*. 2025;189:18–25.**
12. Kvam TM, Goksøyr I, Rog J, van de Vooren ITJ, Stewart L, Berthold-Losleben M, et al. Exploration of MDMA-assisted therapy for major depressive disorder: a proof of principle study. *Neuroscience Applied*. 2024;3:104179.
13. Åman CMH, Kvam T-M, Andreassen O, Rønsen AC. Ketamin har god effekt mot depresjon. *Sykepleien forskning (Oslo)*. 2023(93592):e–93592.
14. Kvam T-M, Uthaug MV, Andersen KAA, Refsum BB, Tunstad PA, Stewart LH, et al. Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. *Frontiers in Psychiatry*. 2023;14.
15. Kvam T-M, Goksøyr IW, Stewart LH, Repantis D, Røssberg JI, Andreassen OA. Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”. *Frontiers in Psychiatry*. 2022;13.

16. Kvam TM, Stewart LH, Blomkvist AW, Andreassen OA. Ketamine for depression - evidence and proposals for practice. *Tidsskr Nor Lægeforen*. 2021;141.
17. Jacobsen HB, Stubhaug A, Holmøy B, Kvam TM, Reme SE. Have Norwegians tried psilocybin, and do they accept it as a medicine? *Journal of Psychedelic Studies*. 2021;5(1):33–6.
18. Goksøyr IW, Kvam T-M, Lund-Høie S, Stewart L. Safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of post-traumatic stress disorder (PTSD) – a systematic review. *Journal of the Norwegian Psychological Association*. 2020;57(12):886–97.
19. Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. *Tidsskr Nor Lægeforen*. 2018;138(18).
20. **Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. *Pain*. 2005;116(1-2):73–8.**
21. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F. Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. *J Mol Med (Berl)*. 2004;82(4):250–5.